If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,632.00    0.00 (0.00%)
Bid:
1,100.00
Ask:
2,200.00
Spread: 1,100.00 (100.00%)
Market Cap: £3.43b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

6 May 2026 15:08

RNS Number : 2912D
Hikma Pharmaceuticals Plc
06 May 2026
 

Hikma Pharmaceuticals PLC

(the "Company")

 

LONDON, 6 May 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibilities ("PDMRs") of the Company acquired Ordinary Shares in the Company, which were purchased under a dividend reinvestment plan ("DRIP").

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities

Hussein Arkhagha

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hussein Arkhagha

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.098

407

d)

Aggregated information

Price(s): £14.098

Volume(s): 407

Total: £5,737.82

e)

Date of the transaction

5 May 2026

f)

Place of the transaction

London Stock Exchange (XLON)

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.098

2,337

d)

Aggregated information

Price(s): £14.098

Volume(s): 2,337

Total: £32,946.63

e)

Date of the transaction

5 May 2026

f)

Place of the transaction

London Stock Exchange (XLON)

Julie Hill

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julie Hill

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.098

178

d)

Aggregated information

Price(s): £14.098

Volume(s): 178

Total: £2,509.41

e)

Date of the transaction

5 May 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Helen Middlemist

Group Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDULGGDGLL
Date   Source Headline
12th Jan 20115:14 pmRNSTotal Voting Rights
12th Jan 201110:13 amRNSDirector/PDMR Shareholding
10th Jan 20113:47 pmRNSDirector/PDMR Shareholding
10th Jan 201111:51 amRNSDirector/PDMR Shareholding
5th Jan 201111:32 amRNSTotal Voting Rights
16th Dec 20105:27 pmRNSDirector/PDMR Shareholding
6th Dec 20104:29 pmRNSDirector/PDMR Shareholding
1st Dec 20104:18 pmRNSDirector/PDMR Shareholding
12th Nov 20107:00 amRNSInterim Management Statement
9th Nov 20109:48 amRNSDirector/PDMR Shareholding
5th Nov 20103:37 pmRNSTotal Voting Rights
4th Nov 20104:15 pmRNSDirector/PDMR Shareholding
2nd Nov 201010:42 amRNSDirector/PDMR Shareholding
29th Oct 20107:00 amRNSAcquisition
18th Oct 20107:00 amRNSProduct Update
15th Oct 201011:10 amRNSBlock Listing for Share Schemes
4th Oct 20105:18 pmRNSTotal Voting Rights
4th Oct 20105:04 pmRNSBlocklisting Interim Review
1st Oct 20107:00 amRNSCompany Update
6th Sep 20103:53 pmRNSTotal Voting Rights
26th Aug 20107:00 amRNSInterim Results
4th Aug 20105:19 pmRNSVoting Rights and Capital
2nd Aug 201012:16 pmRNSAnnual Information Update
26th Jul 20105:30 pmRNSVoting Rights and Capital
13th May 20103:37 pmRNSAGM Statement
13th May 20107:00 amRNSInterim Management Statement
5th May 20105:48 pmRNSVoting Rights & Capital
23rd Apr 20103:16 pmRNSDirector/PDMR Shareholding
20th Apr 201010:02 amRNSDirector/PDMR Shareholding
12th Apr 20109:14 amRNSHikma expands in the Algerian market
9th Apr 20104:33 pmRNSAnnual Financial Report
9th Apr 201012:50 pmRNSDirector/PDMR Shareholding
9th Apr 201012:48 pmRNSDirector/PDMR Shareholding
8th Apr 201010:13 amRNSDirector/PDMR Shareholding
7th Apr 20107:00 amRNSHikma & CellTrion enter an exclusive partnership
7th Apr 20107:00 amRNSDirector/PDMR Shareholding
1st Apr 201012:23 pmRNSVoting Rights & Capital
1st Apr 201012:10 pmRNSBlocklisting Six Monthly return
30th Mar 20109:20 amRNSHikma expands in the Tunisian market
23rd Mar 20104:18 pmRNSDirector/PDMR Shareholding
17th Mar 20107:00 amRNSPreliminary Announcement for 2009
15th Mar 20109:43 amRNSBlocklisting of Shares
10th Mar 201011:00 amRNSTotal Voting Rights
1st Mar 20105:51 pmRNSNotice of Results
1st Feb 20101:40 pmRNSTotal Voting Rights
11th Jan 201012:00 pmRNSNon Regulatory Announcement
5th Jan 20102:10 pmRNSDirector/PDMR Shareholding
4th Jan 20106:28 pmRNSTotal Voting Rights
18th Dec 20093:17 pmRNSDirector/PDMR Shareholding
1st Dec 200910:05 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.